Go to
JCI Insight
Citations to this article
Abstract
Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease characterized by the production of pathogenic autoantibodies. A new study demonstrates that passive antibody specific for the TNF family member, CD154, ameliorates disease by reducing levels of self-reactive antibody in the serum. This study demonstrates a substantial potential for anti-CD154 antibody in the treatment of humoral autoimmunity.
Authors
Garnett Kelsoe
Citation information
Citations to this article (4)
| Title and authors | Publication | Year |
|---|---|---|
|
Protective Role of Myeloid Cells Expressing a G-CSF Receptor Polymorphism in an Induced Model of Lupus
R Sivakumar, G Abboud, CE Mathews, MA Atkinson, L Morel |
Frontiers in immunology | 2018 |
|
Abnormal high-expression of CD154 on T lymphocytes of ankylosing spondylitis patients is down-regulated by etanercept treatment
Q Lin, Z Lin, J Gu, F Huang, T Li, Q Wei, Z Liao, S Cao, Y Jiang, J Huang |
Rheumatology International | 2009 |
|
Human immunoglobulin selection associated with class-switch and possible tolerogenic origins for Cdelta class-switched B cells
Nai-Ying Zheng, Kenneth Wilson, Xiaojian Wang, Angela Boston, Grant Kolar, Stephen M. Jackson, Yong-Jun Liu, Virginia Pascual, J. Donald Capra, and Patrick C. Wilson |
Journal of Clinical Investigation | 2004 |
|
The CD40/CD40L costimulatory pathway in inflammatory bowel disease
S Danese, M Sans, C Fiocchi |
Gut | 2004 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)